Veradermics reports Q3 2026 results, $798.4 million cash, runway into 2030
Company says cash funds operations into 2030 through multiple Phase 3 readouts and potential launch of VDPHL01, with female pattern hair loss data due in 1H27.
SEC filing (3)
2 stories
Company says cash funds operations into 2030 through multiple Phase 3 readouts and potential launch of VDPHL01, with female pattern hair loss data due in 1H27.
SEC filing (3)
Study '304' hit all primary and secondary endpoints, with VDPHL01 beating placebo on hair count and patient-reported improvement at Month 6.
SEC filing